Intel stock spikes after report of possible US government stake
Acadia Pharmaceuticals Inc. stock reached a notable milestone, hitting a 52-week high of 25.24 USD. This achievement reflects a significant upward trajectory over the past year, with the stock delivering an impressive 62.33% return. According to InvestingPro data, the company maintains a "GREAT" financial health score of 3.69, with seven analysts recently revising their earnings expectations upward. The company’s performance in the market has been robust, driving investor confidence and contributing to its rising stock value. This 52-week high marks a period of growth and potential for Acadia Pharmaceuticals, as it continues to capture attention in the pharmaceutical sector. With a market capitalization of $4.19 billion and analyst price targets ranging from $17 to $40, InvestingPro analysis suggests the stock may still have room to run, with 11 additional exclusive insights available to subscribers.
In other recent news, Acadia Pharmaceuticals reported its second-quarter 2025 earnings, surpassing Wall Street expectations with an earnings per share of $0.16, compared to the forecasted $0.14. The company’s revenue reached $264.6 million, slightly exceeding the projected $262.44 million. Acadia’s Nuplazid sales were reported at $168.5 million, aligning with consensus expectations, while Daybue sales came in at $96.1 million, surpassing estimates. Following these results, Stifel raised its price target for Acadia Pharmaceuticals to $24 from $18, maintaining a Hold rating. Mizuho (NYSE:MFG) also increased its price target to $24 from $23, keeping a Neutral rating. Citizens JMP raised their price target to $38 from $37, maintaining a Market Outperform rating. The company’s strong performance with its Nuplazid and Daybue products led management to adjust the lower end of its fiscal year 2025 guidance for Nuplazid. These developments reflect the company’s solid execution and positive reception from analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.